Zymeworks (ZYME)

• Market cap: $1.35B
• 1 day: -1.39%
• 5 days: -6.56%
• 1 month: 6.65%
• 3 months: 43.43%
• 6 months: 51.62%
• Year to date: 20.43%
• 1 year: 14.03%
• 5 years: -57.16%
• 10 years: 36.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 273